-+ 0.00%
-+ 0.00%
-+ 0.00%

BioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55 Unfavorable Impact To GAAP And Non-Gaap Diluted EPS For FY26

Benzinga·10/06/2026 20:33:08

SEC.